# data[].attributes.attachment_link.title
fmolb- August 2022 triple-negative breast cancer Insights into tumor immune landscape and therapeutic opportunities

# data[].attributes.headline
Efficacy of PD-1 & PD-L1 inhibitors in olderadults: a meta-analysis

# data[].attributes.subject
Efficacy of PD-1 & PD-L1 inhibitors in olderadults: a meta-analysis

# data[].attributes.attachment_link.title
Cancer - 2018 - Gulbahce - Differences in molecular features of triple‐negative breast cancers based on the age at

# data[].attributes.headline
Integrated Molecular Profiling of Young and Elderly PatientsWith Triple-Negative Breast Cancer Indicates DifferentBiological Bases and Clinical Management Strategies 2021

# data[].attributes.subject
Integrated Molecular Profiling of Young and Elderly PatientsWith Triple-Negative Breast Cancer Indicates DifferentBiological Bases and Clinical Management Strategies 2021

# data[].attributes.headline
A comparison between young and old patients with triple‑negativebreast cancer: biology, survival and metastatic patterns

# data[].attributes.subject
A comparison between young and old patients with triple‑negativebreast cancer: biology, survival and metastatic patterns

# data[].attributes.headline
GLOBOCAN ESTIMATIVAS  GERAL INCIDENCIA 2020

# data[].attributes.subject
GLOBOCAN ESTIMATIVAS  GERAL INCIDENCIA 2020

# data[].attributes.attachment_link.title
Roche Withdraws Application for Atezolizumab in Early or Locally Advanced TNBC in Europe

# data[].attributes.attachment_link.title
watts_2022_Association of Leisure Time Physical Activity Types and Risks of All-Cause older

# data[].attributes.attachment_link.title
Refining patient selection for breast cancer immunotherapy beyond PD-L1  esmo2021

# data[].attributes.headline
Evaluating the impact of ageon immune checkpoint therapy biomarkers 2021

# data[].attributes.subject
Evaluating the impact of ageon immune checkpoint therapy biomarkers 2021

# data[].attributes.headline
Clinical significance of tumor-infiltratinglymphocytes in breast cancer

# data[].attributes.subject
Clinical significance of tumor-infiltratinglymphocytes in breast cancer

# data[].attributes.headline
Systemic treatment for triple negative breast cancer in older patients:A Young International Society of Geriatric Oncology Review PapeR 2022

# data[].attributes.subject
Systemic treatment for triple negative breast cancer in older patients:A Young International Society of Geriatric Oncology Review PapeR 2022

# data[].attributes.attachment_link.title
Systemic treatment for triple negative breast cancer in older patients 2022

# data[].attributes.headline
Management of patients with early-stage triple-negative breast cancerfollowing pembrolizumab-based neoadjuvant therapy: What arethe evidences?

# data[].attributes.subject
Management of patients with early-stage triple-negative breast cancerfollowing pembrolizumab-based neoadjuvant therapy: What arethe evidences?

# data[].attributes.headline
Pathology of triple negative breast cancer

# data[].attributes.subject
Pathology of triple negative breast cancer

# data[].attributes.headline
Addition of chemotherapy to local therapy in women aged70 years or older with triple-negative breast cancer:a propensity-matched analysis

# data[].attributes.subject
Addition of chemotherapy to local therapy in women aged70 years or older with triple-negative breast cancer:a propensity-matched analysis

# data[].attributes.attachment_link.title
Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer lancet 2020

# data[].attributes.headline
Event-free Survival with Pembrolizumabin Early Triple-Negative Breast Cancer NEJM 2022

# data[].attributes.subject
Event-free Survival with Pembrolizumabin Early Triple-Negative Breast Cancer NEJM 2022

# data[].attributes.headline
The Impact of Age on Assessment and Treatment of Breast Cancer inOlder People: You Are Only as Old as Your Oncologist Thinks You Ar

# data[].attributes.subject
The Impact of Age on Assessment and Treatment of Breast Cancer inOlder People: You Are Only as Old as Your Oncologist Thinks You Ar

# data[].attributes.attachment_link.title
The Impact of Age on Assessment and Treatment of Breast Cancer in 2022

# data[].attributes.headline
Integrated Molecular Profiling of Young and Elderly PatientsWith Triple-Negative Breast Cancer Indicates DifferentBiological Bases and Clinical Management Strategies

# data[].attributes.subject
Integrated Molecular Profiling of Young and Elderly PatientsWith Triple-Negative Breast Cancer Indicates DifferentBiological Bases and Clinical Management Strategies

# data[].attributes.attachment_link.title
Cancer - 2020 - Ma - Integrated molecular profiling of young and elderly patients with triple‐negative breast cancer (1)

# data[].attributes.attachment_link.title
Triple-negative breast cancer in the older population molecular 2021

# data[].attributes.attachment_link.title
Management of Triple-Negative Breast Cancer in Older Patients_ How Is It Different_

# data[].attributes.headline
Triple-negative breast cancer in the older population 2012

# data[].attributes.subject
Triple-negative breast cancer in the older population 2012

# data[].attributes.attachment_link.title
Triple-negative breast cancer in the older population 2012 esmo

# data[].attributes.headline
2017 TNBC ELDERLY  PROGNOSIS AND TREATMENT 

# data[].attributes.subject
2017 TNBC ELDERLY  PROGNOSIS AND TREATMENT 

# data[].attributes.attachment_link.description
Prostate cancer survival prediction tool

# data[].attributes.attachment_link.readable_text
Age Gap Decision Tool feedback survey

We would appreciate it if you could take 2 minutes to provide feedback by completing either the Clinician or Patient survey.

Your feedback will be anonymous. Thank you.

# data[].attributes.attachment_link.description
Age Gap Decision Tool feedback survey We would appreciate it if you could take 2 minutes to provide feedback by completing either the Clinician or Patient survey. Your feedback will be anonymous. Thank you.

# data[].attributes.attachment_link.readable_text
Bellera CA, Rainfray M, Mathoulin-Pelissier S ´ et al. Screening older cancer patients: First evaluation of the G-8 geriatric screening tool. Ann Oncol 2012;23:2166 – 2172

Validation of G8 and its acuracy as a predictor of object in oncological patients with age of ≥ 60 YEARS. prospective cohort of 889 brazilian elderly cancer patients.

Jurema Telles O Lima, Raissa Viana, Letícia telles Sales, Mirella Rebello, José Natal Figueiroa, Anke Bergmann, Zilda Cavalcanti, Amanda L LINS Mello, Maria Julia Gonçalves Mello, Luiz Claudio Santos Thuler, and BROG- Brazilian Research Oncologic Geriatric Group Journal of Clinical Oncology 2019 37:15_suppl, e23036-e23036.

# data[].attributes.attachment_link.description
Bellera CA, Rainfray M, Mathoulin-Pelissier S ´ et al. Screening older cancer patients: First evaluation of the G-8 geriatric screening tool. Ann Oncol 2012;23:2166 - 2172 Validation of G8 and its acuracy as a predictor of object in oncological patients with age of ≥ 60 YEARS. prospective cohort of 889 brazilian elderly cancer patients.

# data[].attributes.attachment_link.readable_text
* Eastern Cooperative Oncology Group (ECOG)

Martinez-Tapia C, Canoui-Poitrine F, Bastuji-Garin S, et al. Optimizing the G8 Screening Tool for Older Patients With Cancer: Diagnostic Performance and Validation of a Six-Item Version. Oncologist. 2016;21(2):188-195. doi:10.1634/theoncologist.2015-0326

Camara DB, Lima JTO, Bezerra MR, et al. Prognostic performance of the modified-G8 screening instrument for patients aged 60 years or older: A prospective cohort of 889 Brazilian patients. J Geriatr Oncol. 2020;11(3):533-535. doi:10.1016/j.jgo.2019.10.021

# data[].attributes.attachment_link.description
Eastern Cooperative Oncology Group (ECOG) Martinez-Tapia C, Canoui-Poitrine F, Bastuji-Garin S, et al. Optimizing the G8 Screening Tool for Older Patients With Cancer: Diagnostic Performance and Validation of a Six-Item Version. Oncologist. 2016;21(2):188-195. doi:10.1634/theoncologist.2015-0326 Camara DB, Lima JTO, Bezerra MR, et al.

# data[].attributes.attachment_link.readable_text
Welcome to the ACS NSQIP Surgical Risk Calculator

Last parameter update: November 2021

With this tool you can enter preoperative information about your patient to provide estimates regarding your patient's risk of postoperative complications.

Effective November 11, 2021, the Risk Calculator is using updated parameters, derived from more current data, to improve already excellent accuracy. Differences in results between the prior and the updated Risk Calculator should be small. While the Risk Calculator has been tested extensively, we are interested in any user observations of unreasonable estimates. Please report these to: nsqiptech@facs.org.

Disclaimer: The ACS NSQIP Surgical Risk Calculator estimates the chance of an unfavorable outcome (such as a complication or death) after surgery. The risk is estimated based upon information the patient gives to the healthcare provider about prior health history. The estimates are calculated using data from a large number of patients who had a surgical procedure similar to the one the patient may have.

Please note the risk percentages provided to you by the Surgical Risk Calculator are only estimates. The risk estimate only takes certain information into account. There may be other factors that are not included in the estimate which may increase or decrease the risk of a complication or death. These estimates are not a guarantee of results. A complication after surgery may happen even if the risk is low. This information is not intended to replace the advice of a doctor or healthcare provider about the diagnosis, treatment, or potential outcomes. ACS is not responsible for medical decisions that may be made based on the risk calculator estimates, since these estimates are provided for informational purposes. Patients should always consult their doctor or other health care provider before deciding on a treatment plan.

Risk Calculator Permitted Use: An external platform (e.g., an electronic health record) may open the web address of the ACS NSQIP surgical risk calculator in a new browser window. However, we do not permit the calculator to appear as an integrated feature of any external platform, nor do we permit the functionality of the calculator to be automated in any way. The calculator must be presented in its original, unaltered form, maintaining all ACS branding and copyright information.

Step 1 of 4

# data[].attributes.attachment_link.description
Last parameter update: November 2021 With this tool you can enter preoperative information about your patient to provide estimates regarding your patient's risk of postoperative complications. Effective November 11, 2021, the Risk Calculator is using updated parameters, derived from more current data, to improve already excellent accuracy.

# data[].attributes.attachment_link.description
The mission of the Cancer and Aging Research Group is to join geriatric oncology researchers across the nation in a collaborative effort of designing and implementing clinical trials to improve the care of older adults with cancer. The only requirement for membership is the desire to help older adults with cancer.

# data[].attributes.attachment_link.readable_text
Links
ePrognosis' Sister Site:

Other sites with prognosis calculators:

Cancer:

Breast Cancer Prediction

EFFECT In-hospital Heart Failure Mortality Prediction

Hodgkin Lymphoma

Cancer Survival Rates

Cardiology:

10-year Framingham risk to decide on statin treatment

Atrial Fibrillation Risk

Cardiovascular Risk Assessment in adults (10-year, MESA 2015, with or without CAC score)

Cerebrovascular:

Grace Score for 6-month mortality after ACS

Seattle Heart Failure

CHADSVasc2

GO-FAR Calculator for neurologically intact survival after in-hospital arrest

HAS-BLED Score

Endocrine:

Risk of TIA Progression

Stroke Risk Female

Stroke Risk Male

Gastrointestinal:

FRAX probability of fracture

Child Pugh Score for Severity of Liver Disease

General Life Expectancy:

Liver Failure MELD Score

MD Calc

Nephrology:

Non-medical actuarial calculator for life expectancy

Cohen Index 6-month mortality for patients on hemodialysis

Pulmonary:

CURB-65 Pneumonia Severity Score

Urology:

IPSS score for prostate symptoms

# data[].attributes.attachment_link.title
The Use and Knowledge of Validated GA geriatric oncology jpo

# data[].attributes.attachment_link.title
Prospective comparison of the value of CRASH and CARG

# data[].attributes.attachment_link.readable_text
Overview

The Global Breast Cancer Initiative, established by WHO in 2021, will provide guidance to governments on health systems strengthening for breast cancer. This illustrated summary outlines its goals, rationale and framework.

# data[].attributes.attachment_link.title
The Global Breast Cancer Initiative (GBCI)

# data[].attributes.attachment_link.description
﻿The Global Breast Cancer Initiative, established by WHO in 2021, will provide guidance to governments on health systems strengthening for breast cancer. This illustrated summary outlines its goals, rationale and framework.

# data[].attributes.attachment_link.title
Breast Cancer global quality care optimizing care delivery with existing financial and personnel resources ESMO

# data[].attributes.attachment_link.title
The Breast Health Global Initiative 2018 Global Summit on cancer 2020

# data[].attributes.attachment_link.title
Molecular alterations in triple-negative breast cancer LANCET 3

# data[].attributes.attachment_link.embed_code
View this post on Instagram

A post shared by Oncogeriatria Brasil (@oncogeriatriabrasil)

# data[].attributes.attachment_link.embed_code
View this post on Instagram

A post shared by Oncogeriatria Brasil (@oncogeriatriabrasil)